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ABSTRACT 
Non Alcoholic Fatty Liver Disease (NAFLD) is a reversible condition of the liver, wherein large 
vacuoles of triglyceride fat accumulates in liver cells via the process of steatosis, despite any 
evidence of excessive alcohol consumption. In view of present scenario of high prevalence and 
limited treatment options, this study was conducted to assess the effect of Murabba-i- Zanjabīl in 
NAFLD. Present study was designed as a randomized placebo controlled trial with 30 patients in 
test group and 10 patients in control group. Participants in test group were administered with 
Murabba-i- Zanjabīl, 5 gm twice daily, 30 minutes before food for 45 days and those in control 
group were given 1 capsule of 500 mg each containing wheat flour twice daily, 30 minutes before 
food for 45 days. All the participants were asked to follow up at every 15 days for assessment of 
subjective parameters. Objective parameter was assessed before and after the trial period. On 
statistical analysis the test formulation showed significant reduction in scores (p<0.05) for most of 
the parameters on both inter and intra group analysis, while the reduction in control group was 
not found to be statistically significant (p.0.05). This study lays out that Murabbā-i Zanjabīl in a 
dose of 5gm twice daily given for 45 days is more effective than placebo in treating NAFLD. There 
was no adverse effect reported during the trial. It was thus concluded that Murabbā-i Zanjabīl is 
effective and safe in therapeutic management of NAFLD. 
KEYWORDS: Su’-i Mizāj Kabid Bārid, Non-Alcoholic Fatty Liver Disease, NAFLD, Murabbā-i 
Zanjabīl, Unani Medicine. 
INTRODUCTION 
 Non Alcoholic Fatty Liver Disease (NAFLD) is 
a reversible condition of the liver, wherein large 
vacuoles of triglyceride fat accumulates in liver cells 
via the process of steatosis (abnormal retention of 
lipids within a cell), despite any evidence of excessive 
alcohol consumption.[1] In the developed countries 
NAFLD is reported to be the most common liver 
disorder, with a worldwide prevalence of 6%-35% 
and 25%-26% in Europe. In Asian countries the 
pooled prevalence of NAFLD is estimated to be 27.4% 
(95% CI 23.3%-31.9%). It occurs in all age groups 
including children, with highest prevalence between 
40 to 49 years of age and equal distribution among 
males and females. 
For a significant amount of time fatty 
infiltration of liver was not thought to be of much 
clinical significance. However it was acknowledged 
that similar to alcohol induced liver disease obese 
and diabetic patients may also show pathological 
changes in liver. But these problems were given 
importance after it was established that NAFLD exists 
as a spectrum of diseases ranging from simple 
steatosis without any evidence of cell injury to non-
alcoholic steatohepatitis, which has the potential to 
progress to cirrhosis. NAFLD has a close relationship 
with obesity, insulin resistance and dyslipidemia. 
Majority of the patients with fatty liver also present 
with insulin resistance and metabolic syndrome, 
accompanied with central or visceral obesity. With 
the obesity emerging as a worldwide epidemic, a 
great amount of research is in progress.[2] 
The patients may remain asymptomatic 
during the initial phase of the disease. Most patients 
have an accidental diagnosis of the disease when they 
undergo imaging for some other problem. Patients 
may sometimes also be symptomatic and present 
with features of dull ache/ heaviness in right 
hypochondrium, anorexia, nausea, vomiting and 
dyspepsia. Hepatomegaly is present in up to 75% of 
patients, but stigmata of chronic liver disease are 
uncommon.[2,3] 
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Laboratory studies may show mildly elevated 
aminotransferase and alkaline phosphatase levels; 
however laboratory values may be normal in up to 
80% of people with fatty liver. Biopsy remaining the 
gold standard for diagnosis, imaging also provides a 
clear picture of the disease when other diseases like 
viral hepatitis, autoimmune liver disease, Wilson’s 
disease, hemochromatosis and α1 antitrypsin 
deficiency are excluded.[2,4,5,6] 
Unani physicians have described liver as one 
of the principal organs of the body (Aaza e raeesa).[7] 
It is the primary source of natural faculties (Quwwate 
Tabiya), where the functions of digestion, concoction, 
absorption and excretion are performed.[8,9] Normally 
mizaj of liver is hot and moist,[9-12] which can get 
converted to cold due to mutable dietary habits, 
consumption of fatty and cold food in abundance etc., 
thereby allowing excessive accumulation of fat in 
liver parenchyma (Tashhamul kabid). This alteration 
in mizaj (Su’-i Mizāj Kabid Bārid) results in alteration 
in liver functioning which ultimately leads to 
formation of Akhlate Raddiya (abnormal 
humors).[11,13,14] One of the basic modalities of 
treatment, recommended by Unani physician for Su’-I 
Mizāj Kabid Bārid is Ilājbi’lZid, by using the drugs of 
opposite temperament than the disease. Zanajbīl 
(Zingiberofficinale), having Mizāj as HārYābis, [15-21] 
has been in practice of ancient Unani physicians to 
treat Su’-I Mizāj Kabid Bārid. Various Unani 
physicians like Ibn-i Sīna (Al-Qānūnfi’l-Tib),[14] Hakīm 
Najmal-Ghani (Khazāinal-Advia),[16] Ibn-i Baiṭār 
(Kitāb al-Mukhtārātfi’l-Tib),[22] Hakīm Muhammad 
Aʻzam Khan (Muhīt-I Aʻzam)[15] has mentioned 
Zanjabīl to be Muqawwi-I Jigar, and to be effective in 
Baroodat e jigarin the form of Murabbā (Pickle). Ibn-i 
Baitār also recommended Murabbā-I Sonth to be a 
remedy for Su’-I Mizāj Kabid Bārid.[22] 
Materials and Methods 
Study Design 
The study was carried out as an open label 
placebo controlled trial in the department of Moalajat 
of National Institute of Unani Medicine Hospital, 
Bengaluru, for duration of one year, i.e. from January 
2018 to January 2019. Before the commencement of 
the trial, the study protocol was drafted and 
submitted to the institutional ethical committee for 
approval. The study was approved by the Ethics 
committee of NIUM, Bengaluru under IEC number 
NIUM/IEC/2016-17/004/Moal/04, and dated 
18.05.2017. The trial was registered by the Clinical 
Trial Registry of India under clinical trial registration 
number CTRI/2018/01/011531.  
Study Participants 
A total of 180 patients were screened for the 
study. 106 patients were selected based on 
ultrasonography scan. Out of these, 56 patients 
denied participation in the study. 50 patients were 
investigated for study participation out of which 10 
patients did not meet the inclusion criteria and only 
40 were included in the study. 30 patients fulfilling 
the inclusion criteria were randomly assigned to the 
test group while 10 to the control group (Fig.1). The 
patients enrolled were clinically assessed by history 
taking and clinical examination of all the systems and 
other required parameters. All the information was 
recorded in the case record form designed for the 
study. Patients were then enrolled in the study after 
taking written informed consent. All the patients 
were given a diet chart to be followed during the trial 
period and a compliance chart that was to be filled by 
the patient himself to ensure patient compliance of 
drug, diet and exercise. 
Randomization 
Subject allocation was done by simple 
randomization technique using a computer generated 
random allocation table. 
Inclusion and Exclusion Criteria 
The patients from the OPD/IPD of NIUM 
hospital, diagnosed as having fatty liver grade I and II 
based on the ultrasonography report and without any 
history of alcohol intake were enrolled in the study. 
Patients with/ without clinical signs and symptoms 
like Anorexia, Nausea, Dyspepsia, Fatigue, Dull ache/ 
Heaviness in right hypochondriac region and 
Hepatomegaly, of either gender between 18-60 years 
of age, non-alcoholic and diagnosed with fatty liver 
grade I or II on an ultrasonogram were included in 
the study. Those diagnosed with fatty liver grade III 
and positive viral hepatitis markers were excluded 
from the study. Moreover, patients suffering from any 
sort of systemic illness and pregnant and lactating 
women were also not taken to be the participants. 
Patients with a positive HbsAg and increased random 
blood sugar were also excluded. 
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Fig.1: Consort Flow Diagram
Measurements 
All the patients, either presenting with the 
symptoms or accidentally diagnosed with fatty liver 
in ultrasonogram done for some other purpose, were 
evaluated for the complaints of dull ache/ heaviness 
in right hypochondriac region, anorexia, nausea and 
dyspepsia in the general OPD (Moalajat)/IPD. 
Patients, who were known cases of diabetes mellitus, 
were diagnosed with grade III fatty liver or alcoholics 
were excluded from the study. In each patient 
complete physical examination was done including 
presenting complaints, past history, family history, 
general physical examination and systemic 
examination. Height and weight of the patients was 
measured and their BMI was calculated according to 
the formula BMI= Weight in KG/ Height in M2. Then 
the patients underwent biochemical and pathological 
investigations like Hb%, TLC, DLC, ESR, SGOT (AST), 
SGPT (ALT), Alkaline Phosphatase, Blood urea, Serum 
Creatinine, Blood Sugar (Random) and HbsAg to 
exclude any systemic illness.  
 
 
 
Preparation 
For preparation of Murabba-i- Zanjabīl, Fresh 
ginger was first peeled and then boiled in water until 
it became soft. After that Qiwam (Syrup) of sugar was 
made with quantity equal to that of ginger and then 
soften ginger was put in it and left overnight. If 
qiwam became dilute the next day, it was boiled again 
without the soften ginger in it to vaporize excess 
water content. If on the third day again Qiwam 
appears to be dilute then it is again boiled.[23-26] 
Intervention 
Patients in the test group were administered 
Murabba-i- Zanjabīl in a dose of 5gm twice a day, 30 
minutes before meals, orally and those in control 
group were given wheat flour capsules of 500 mg 
each, 1 capsule twice a day, 30 minutes before meals. 
After enrolment in the study patients were asked to 
visit the hospital after every 15 days for a period of 
45 days (3 visits after first visit). During each visit 
patients were assessed for the progression or 
regression of subjective symptoms. Grading of fatty 
liver by ultrasonogram was done before and after the 
study. 
Assessed for eligibility  
n=50 
Randomized 
 n=40 
Excluded n= 10 
Diabetes Mellitus = 9 
HbsAg positive = 1 
 
 
 
Allocated to test group n= 30 
Received test drug n= 30 
Allocated to control group n= 10 
Received control drug n= 10 
Lost to follow up n= 4 
Analyzed n= 30 
 
Lost to follow up n= 2 
Analyzed n= 30 
 
Patients screened  
n= 180 
Patients selected 
n= 106 
Denied participation  
n=56 
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Dietary advice and lifestyle modification 
Patients in both groups were asked to follow 
the diet chart provided at the time of first visit and 
were asked to do 30-45 minutes of brisk walking 
daily in morning and evening. They were also given a 
compliance chart to record whether they followed all 
the dos and don’ts daily or not. 
Outcome Measurements 
Efficacy assessment was done on the basis of 
improvement in subjective and objective parameters. 
Objective parameter (i.e. fatty liver grade) was 
assessed by ultrasonography while an arbitrary 
assessment scale was adopted for the assessment of 
subjective parameters (i.e. dull ache/heaviness in the 
right upper quadrant, Anorexia, Nausea, Dyspepsia). 
S No Nature Grade Score Nature of severity 
1 No - 0 No symptoms 
2 Mild + 1 Mild Symptoms but not enough to require remedial therapy to 
carry out daily routine 
3 Moderate ++ 2 Moderate symptoms which interfere with daily routine and 
require remedial therapy to continue to work 
4 Severe +++ 3 Severe symptoms which do not allow daily activities 
Safety assessment was done on Clinical 
symptoms and reporting of side effects, if any, and 
Laboratory Investigations such as Hematological 
assessment (Hb%, TLC, DLC, ESR), Biochemical 
assessment (SGOT (AST), SGPT (ALT), Alkaline 
Phosphatase, Blood urea, Serum Creatinine). 
Statistical Analysis 
Descriptive and inferential statistical analysis has 
been carried out in the present study. Results on 
continuous measurements are presented on Mean  
SD (Min-Max) and results on categorical 
measurements are presented in Number (%). 
Significance is assessed at 5 % level of significance. 
The following assumptions on data is made- 
1. Dependent variables should be normally 
distributed,  
2. Samples drawn from the population should be 
random,  
3. Cases of the samples should be independent 
Student t test (two tailed, independent) has 
been used to find the significance of study 
parameters on continuous scale between two groups 
(Inter group analysis) on metric parameters. Leven`s 
test for homogeneity of variance has been performed 
to assess the homogeneity of variance. Student t test 
(two tailed, dependent) has been used to find the 
significance of study parameters on continuous scale 
within each group. Chi-square/ Fisher Exact test has 
been used to find the significance of study 
parameters on categorical scale between two or more 
groups, Non-parametric setting for Qualitative data 
analysis. Paired Proportion test has been used to find 
the significance of proportion in paired data. Smaller 
percentage of Improvement becomes significant at 
lower tail compared to higher tail. E.g. Improvement 
from 10% to 20% is difficult than the Improvement 
from 80% to 90% 
 
Results 
There was no difference in the demographic 
characteristics between the two groups depicting 
homogeneity (Table 1). Difference in improvement 
between test and control groups for Dull ache/ 
heaviness in right hypochondrium was highly 
significant with p value <0.001. Also the 
improvement in test and control group individually 
was statistically significant (Table 2). In Anorexia 
there was a significant improvement reported in the 
test group (p<0.001) while the improvement in the 
control group was not statistically significant (p= 
0.267). On analyzing between test group and control 
group the difference between the test and control 
group result was statistically significant (p=0.002) 
(Table 3).Both the test and control group did not 
show statistically significant improvement in Nausea 
but comparing the two groups the p value was 0.058 
implying suggestive significance at second and third 
follow ups (Table 4). Statistically significant 
improvement was observed in dyspepsia in test 
group (p<0.001) and not in control group (p= 0.285). 
Analyzing between groups improvement was highly 
significant in the test group as compared to the 
placebo with a p value of <0.001 at second and final 
follow up (Table 5). The difference in fatty liver 
grading between the two groups was statistically 
significant with a p value of 0.002 before and after 
intervention (Table 6). There was no significant 
difference between safety profile before and after the 
treatment except for hemoglobin percentage and 
erythrocyte sedimentation rate (ESR) (Table 7). No 
adverse events were noted during the study. 
DISCUSSION 
The result on hypochondriac dullness and 
pain is in accordance with the study conducted by 
Attilio Giacosa et al where a combination of ginger 
and artichoke is reported to bring about a 
significance decrease in abdominal pain after 4 
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weeks of administration.[27] Efficacy of ginger in 
relieving pain has been compared to some NSAIDs 
where ginger extract was found to be equally 
effective as compared to ibuprofen in relieving 
pain.[28] This effect is due to the anti-inflammatory 
and analgesic property of ginger.[29] Experimental 
studies have shown that ginger constituents inhibit a 
key pathway in inflammatory process i.e. aracidonic 
acid metabolism. Also, it acts as inhibitor of 
prostaglandins and leukotriene synthesis by 
suppressing cyclooxygenase and lipooxygenase 
pathways.[29-31] Zingerone, a bioactive component of 
ginger has been suggested to reduce 
lipopolysaccharide (LPS) induced inflammation in 
mice by inhibiting infiltration of inflammatory cells 
and suppressing LPS induced NF-κβ activities in 
cells.32 Also in vitro studies have been carried out on 
6-, 8-, 10- gingerol and 6- shogaol isolated from 
ginger rhizome.[33]  
Anorexia results due to delayed gastric 
emptying developing in patients a feeling of satiety 
thereby decreasing the feeling of hunger. Giacaso et 
al studied the effect of 100 mg ginger extract on 
gastrointestinal motility and reported a significant 
increase in gastrointestinal motility as compared to 
the placebo.[34] Wu et al. reported that ginger 
stimulates antral contractions thereby accelerating 
gastric emptying.[35] Other studies on functional 
dyspepsia have also shown similar effects without 
affecting gut hormones.[36] 
Antiemesis through ginger could be explained 
by several mechanisms. 6-gingerol accelerates 
gastrointestinal transport; it also has been reported 
to exhibit anti hydroxyl tryptamine activity in 
isolated guinea pig ileum.[37] This finding is annealed 
by the fact that 6-gingerol effectively prevented 
cyclophosphamide induced vomiting in animal 
model.[38] Another constituent of ginger 
galanolactone is shown to be a competitive 
antagonist at ileal 5-HT3 receptors.[39] The effect of 
ginger on nausea observed in this study was not 
found in concordance with the result of previous 
studies which have shown ginger to be significantly 
effective in all types of nausea vomiting, i.e. 
pregnancy induced nausea vomiting, post-operative 
nausea vomiting and chemotherapy induced nausea 
vomiting.[27,34,36,38] The reason for this observation 
could be the small sample size of the study with a 
very little occurrence of nausea in patients with 
NAFLD.  
Owing to its carminative activity, ginger 
decreases the pressure on lower esophageal 
sphincter and impedes intestinal cramping thus 
relieving dyspepsia.[36] In previous randomized 
placebo controlled trials similar results have been 
noticed where ginger was reported to be more 
effective as compared to placebo in treating 
dyspepsia.[27,40] Ginger is also known to exhibit 
spasmolytic action thus increasing the gastric 
emptying rates without having any effect on gut 
hormones, ultimately improving the symptoms of 
dyspepsia.[41] 
In a placebo controlled randomized trial 
conducted by Rahimlou et al, 44 patients with NAFLD 
were administered with 2g ginger or placebo per day 
for 12 weeks with similar dietary modification and 
physical activity in each group. The result showed a 
significance decrease in hepatic steatosis.[42] In this 
study also similar effect has been observed. 
Table 1: Baseline Characteristics 
 Test Group (n=30) No. (%) Control Group (n=10) No. (%) p-value 
Age in Years 
Mean + SD 40.53 + 8.63 44.1±7.83 P=0.2552a 
Gender    
Female 14 (46.7%) 7 (70%)  
Male 16 (53.3%) 3 (30%) P=0.201c 
Occupation 
Business 6 (20%) 1 (10%) P=0.457b 
Employee 6 (20%) 3 (30%)  
House wife 11 (36.7%) 6 (60%)  
Labour 6 (20%) 0 (0%)  
Unemployed 1 (3.3%) 0 (0%)  
Marital Status 
Married 25 (83.3%) 10 (100%) P=0.667b 
Unmarried 5 (16.7%) 0 (0%)  
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Socio Economic Status 
Lower 1 (3.3%) 2 (20%) P=0.220b 
Lower Middle 6 (20%) 2 (20%)  
Upper 1 (3.3%) 0 (0%)  
Upper Lower 15 (50%) 6 (60%)  
Upper Middle 7 (23.3%) 0 (0%)  
BMI 
Mean+SD 28.08±3.51 30.50±4.59 P=0.090a 
Diet distribution 
Mixed 27 (90%) 10 (100%) P=0.560b 
Vegetarian 3 (10%) 0 (0%)  
a=Student’s t-test b=Fisher exact test c=Chi-square test 
Table 2: Dull Ache/Heaviness 
Dull Ache/ 
Heaviness 
Baseline 1st follow 
up 
2nd follow 
up 
3rd follow 
up 
% 
difference 
Group TG (n=30) 
0 2 (6.7%) 7 (23.3%) 24 (80%) 30 (100%) 93.3% 
1 11 (36.7%) 21 (70%) 6 (20%) 0 (0%) -36.7% 
2 15 (50%) 2 (6.7%) 0 (0%) 0 (0%) -50.0% 
3 2 (6.7%) 0 (0%) 0 (0%) 0 (0%) -6.7% 
Group CG (n=10) 
0 3 (30%) 3 (30%) 4 (40%) 5 (50%) 20.0% 
1 1 (10%) 3 (30%) 3 (30%) 4 (40%) 30.0% 
2 6 (60%) 4 (40%) 3 (30%) 1 (10%) -50.0% 
3 0 (0%) 0 (0%) 0 (0%) 0 (0%) 0.0% 
P value 0.129 0.205 0.009** <0.001** - 
Chi-Square/Fisher Exact Test 
Group TG: P<0.001**, Significant, paired proportion test, 93.3% Improvement 
Group CG: P<0.001**, Significant, paired proportion test, 50.0% improvement 
Table 3: Anorexia 
Anorexia Baseline 1st follow up 2nd follow up 3rd follow up % difference 
Group TG (n=30) 
0 15 (50%) 26 (86.7%) 30 (100%) 30 (100%) 50.0% 
1 13 (43.3%) 4 (13.3%) 0 (0%) 0 (0%) -43.3% 
2 2 (6.7%) 0 (0%) 0 (0%) 0 (0%) -6.7% 
3 0 (0%) 0 (0%) 0 (0%) 0 (0%) 0.0% 
Group CG (n=10) 
0 4 (40%) 5 (50%) 6 (60%) 6 (60%) 20.0% 
1 6 (60%) 5 (50%) 4 (40%) 4 (40%) -20.0% 
2 0 (0%) 0 (0%) 0 (0%) 0 (0%) 0.0% 
3 0 (0%) 0 (0%) 0 (0%) 0 (0%) 0.0% 
P value 0.840 0.029* 0.002** 0.002** - 
Chi-Square/Fisher Exact Test 
Group TG: P<0.001**, Significant, paired proportion test, 50.0% Improvement 
Group CG: P=0.267, Not Significant, paired proportion test, 20.0% improvement 
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Table 4: Nausea 
Nausea Baseline 1st follow up 2nd follow up 3rd follow up % difference 
Group TG (n=30) 
0 22 (73.3%) 29 (96.7%) 30 (100%) 30 (100%) 26.7% 
1 6 (20%) 1 (3.3%) 0 (0%) 0 (0%) -20.0% 
2 2 (6.7%) 0 (0%) 0 (0%) 0 (0%) -6.7% 
Group CG (n=10) 
0 8 (80%) 8 (80%) 8 (80%) 8 (80%) 0.0% 
1 2 (20%) 2 (20%) 2 (20%) 2 (20%) 0.0% 
2 0 (0%) 0 (0%) 0 (0%) 0 (0%) 0.0% 
P value 1.000 0.149 0.058+ 0.058+ - 
Chi-Square/Fisher Exact Test 
Group TG: P=0.133, Not Significant, paired proportion test, 26.7% Improvement 
Group CG: P=1.000, Not Significant, paired proportion test, 0.00% improvement 
Table 5: Dyspepsia 
Dyspepsia Baseline 1st follow up 2nd follow up 3rd follow up % difference 
Group TG (n=30) 
0 8 (26.7%) 15 (50%) 28 (93.3%) 29 (96.7%) 70.0% 
1 4 (13.3%) 15 (50%) 2 (6.7%) 1 (3.3%) -10.0% 
2 18 (60%) 0 (0%) 0 (0%) 0 (0%) -60.0% 
Group CG (n=10) 
0 4 (40%) 4 (40%) 4 (40%) 4 (40%) 0.0% 
1 1 (10%) 2 (20%) 2 (20%) 2 (20%) 10.0% 
2 5 (50%) 4 (40%) 4 (40%) 4 (40%) -10.0% 
P value 0.869 0.004** <0.001** <0.001** - 
Chi-Square/Fisher Exact Test 
Group TG: P<0.001**, Significant, paired proportion test, 70.0% Improvement 
Group CG: P=0.285, Not Significant, paired proportion test, 10.0% improvement 
Table 6: Fatty liver grading 
Fatty liver grading Before Treatment After Treatment % difference 
Group TG (n=30) 
0 0 (0%) 17 (56.7%) 56.7% 
1 26 (86.7%) 13 (43.3%) -43.4% 
2 4 (13.3%) 0 (0%) -13.3% 
Group CG (n=10) 
0 0 (0%) 0 (0%) 0.0% 
1 10 (100%) 10 (100%) 0.0% 
2 0 (0%) 0 (0%) 0.0% 
P value 0.556 0.002** - 
Chi-Square/Fisher Exact Test 
Group TG: P<0.001**, Significant, paired proportion test, 56.7% Improvement 
Group CG: P=1.000, Not Significant, paired proportion test, 0.0% improvement 
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Table 7: safety profile 
 Test Group Control Group Total P value 
Hemoglobin (g/dl) 
Before Treatment 13.22±1.99 13.18±1.58 13.21±1.88 0.954 
After Treatment 13.76±1.84 13.50±1.27 13.70±1.70 0.678 
Difference -0.543 -0.320 -0.488 - 
P value 0.031* 0.595 0.038* - 
TLC (Cells/cumm) 
Before Treatment 7109.33±1729.62 7090.00±3061.75 7104.50±2094.73 0.980 
After Treatment 6772.67±1569.47 7620.00±1868.93 6984.50±1666.06 0.167 
Difference 336.667 -530.000 120.000 - 
P value 0.191 0.587 0.691 - 
Polymorphs 
Before Treatment 60.24±8.18 60.40±9.17 60.28±8.32 0.959 
After Treatment 58.64±8.41 61.00±9.39 59.23±8.60 0.460 
Difference 1.600 -0.600 1.050 - 
P value 0.250 0.855 0.418 - 
Eosinophils 
Before Treatment 4.77±1.25 4.10±1.45 4.60±1.32 0.168 
After Treatment 4.87±1.25 3.70±1.25 4.58±1.34 0.015* 
Difference -0.100 0.400 0.025 - 
P value 0.703 0.399 0.912 - 
Basophils 
Before Treatment 0.06±0.23 0.00±0.00 0.05±0.20 0.418 
After Treatment 0.06±0.23 0.00±0.00 0.05±0.20 0.418 
Difference - - - - 
P value - - - - 
Monocytes 
Before Treatment 4.14±1.78 3.50±1.65 3.98±1.75 0.322 
After Treatment 4.37±1.73 3.60±1.58 4.18±1.71 0.219 
Difference -0.233 -0.100 -0.200 - 
P value 0.428 0.832 0.416 - 
ESR (mm/1hr) 
Before Treatment 31.63±21.95 29.80±22.76 31.18±21.88 0.822 
After Treatment 20.67±17.82 26.10±22.55 22.03±18.95 0.439 
Difference 10.967 3.700 9.150 - 
P value 0.001** 0.687 0.007** - 
     
Variables Test Group Control Group Total P value 
Serum Creatinine (mg/dl) 
Before Treatment 0.84±0.14 0.80±0.07 0.83±0.12 0.388 
After Treatment 0.85±0.12 0.84±0.12 0.85±0.12 0.848 
Difference -0.009 -0.040 -0.017 - 
P value 0.637 0.269 0.320 - 
Blood Urea (mg/dl) 
Before Treatment 26.28±7.33 25.30±5.81 26.04±6.93 0.702 
After Treatment 25.55±7.71 28.60±7.17 26.31±7.61 0.278 
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Difference 0.733 -3.300 -0.275 - 
P value 0.438 0.227 0.778 - 
Serum Bilirubin (mg/dl) 
Before Treatment 0.66±0.22 0.67±0.21 0.66±0.22 0.856 
After Treatment 0.72±0.27 0.62±0.20 0.69±0.26 0.283 
Difference -0.061 0.056 -0.032 - 
P value 0.239 0.548 0.478 - 
AST (IU/L) 
Before Treatment 28.70±14.02 25.00±6.75 27.78±12.62 0.429 
After Treatment 26.03±8.80 28.80±7.89 26.73±8.57 0.384 
Difference 2.667 -3.800 1.050 - 
P value 0.263 0.234 0.591 - 
ALT (IU/L) 
Before Treatment 31.23±13.97 27.30±11.15 30.25±13.30 0.425 
After Treatment 30.03±12.25 29.90±10.16 30.00±11.63 0.975 
Difference 1.200 -2.600 0.250 - 
P value 0.673 0.405 0.912 - 
Alkaline Phosphatase (IU/L) 
Before Treatment 216.90±65.25 238.60±35.73 222.33±59.59 0.325 
After Treatment 213.37±65.82 246.30±43.72 221.60±62.22 0.150 
Difference 3.533 -7.700 0.725 - 
P value 0.606 0.538 0.902 - 
Future recommendations 
Further controlled clinical trials including 
blinding and more comprehensive study designs with 
large sample size and life style modification and diet 
regulation as control are needed. Since ginger was 
reported to be heptatonic it can also be given as an 
adjuvant with drugs that are known to be 
hepatotoxic. Moreover, further studies can be 
conducted using ginger including grade III fatty liver 
as well.  
CONCLUSION 
After 45 days of treatment the subjective 
symptoms namely dull ache /heaviness in right 
hypochondrium, anorexia, nausea, dyspepsia and 
objective symptom i.e. fatty liver grade were found to 
have significant reduction in score. It was thus 
concluded that Murabbā-i Zanjabīl in a dose of 5gm 
twice daily given for 45 days is more effective than 
placebo in treating NAFLD. 
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